The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes

BACKGROUND: A previous phase I study showed that the infusion of autologous Tregs expanded ex vivo into patients with recent-onset type 1 diabetes (T1D) had an excellent safety profile. However, the majority of the infused Tregs were undetectable in the peripheral blood 3 months postinfusion (Treg-T...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Shen, Hiam-Galvez, Kamir J., Mowery, Cody T., Herold, Kevan C., Gitelman, Stephen E., Esensten, Jonathan H., Liu, Weihong, Lares, Angela P., Leinbach, Ashley S., Lee, Michael, Nguyen, Vinh, Tamaki, Stanley J., Tamaki, Whitney, Tamaki, Courtney M., Mehdizadeh, Morvarid, Putnam, Amy L., Spitzer, Matthew H., Ye, Chun Jimmie, Tang, Qizhi, Bluestone, Jeffrey A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2021
Materias:
Clinical Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492314/
https://www.ncbi.nlm.nih.gov/pubmed/34324441
http://dx.doi.org/10.1172/jci.insight.147474

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492314/
https://www.ncbi.nlm.nih.gov/pubmed/34324441
http://dx.doi.org/10.1172/jci.insight.147474

Ejemplares similares